Genetron Health and Yingpai Pharmaceutical Co., Ltd. reached a cooperation to jointly promote the development of synthetic lethal pipeline

Beijing, September 27, 2021/PRNewswire/ - Today, Genetron Health (Nasdaq: GTH) and Impair Pharmaceutical announced that the two parties have reached a project cooperation in the process of drug research and subsequent development, in order to jointly promote the Research on synthetic lethal inhibitors of new targets and development of accompanying diagnostic products

Synthetic lethal therapies are an emerging field of tumor treatment and have huge market potential

Wang Sizhen, co-founder and CEO of Genetron Health, said: "We are very pleased to have reached a cooperation with Impair Pharmaceuticals

Dr.

About Synthetic Lethality

Synthetic Lethality refers to the phenomenon in which two non-lethal genes are simultaneously inactivated resulting in cell death

About Panshengzi

Genetron Health (Nasdaq: GTH) is a global cutting-edge cancer precision medicine company, focusing on cancer genomics research and applications, and is committed to changing the way of cancer diagnosis and treatment relying on advanced molecular biology and big data analysis capabilities

About Impair Pharmaceutical

Impair Pharmaceutical is committed to the research and development of targeted anti-cancer innovative drugs with independent intellectual property rights, focusing on the synthesis of lethal action mechanisms

Safe Harbor Statement

This press release contains Genetron Health's future expectations, plans and forward-looking statements, which are subject to corresponding risks and uncertainties, which may cause actual results to differ from the expectations described in the forward-looking statements

Source: Genetron Health